Skip to content

Study · Non-randomized trial · n = 15 · 1999

4 results

[Thymalin in the combined treatment of parkinsonism patients].

Musienko GV

Likars'ka sprava1 Jan 1999

PMID10424021 (opens in a new tab)PepBankPUB-10424021
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In idiopathic parkinsonism, general physical and mental well-being improved during thymalin treatment.

    In plain wordsIn patients with idiopathic parkinsonism, general physical and mental well-being improved during thymalin treatment.

    Peptide
    Thymalin
    Outcome
    IncreaseGeneral physical and mental well-being
    Study

    n = 15

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A positive time-related course was noted of the patients' general physical/mental well-being, parkinsonian triad of symptoms (tremor, rigidity, hypokinesia) associated with objective parameters characterizing the state of cerebral integrative functions (by the method of determining the biological ag…
    1 context sentence
    Summary · context
    Overall, fifteen patients with stage IB-2A (stages 1.5 to 2.5 as per UPDRS scale) idiopathic parkinsonism who ranged from 45 to 72 years old were examined before and after the course of treatment with thymalin.
  2. 02HumanNon-randomized trialEfficacy outcome

    In idiopathic parkinsonism, the triad of tremor, rigidity and hypokinesia showed a positive course during thymalin treatment.

    In plain wordsIn patients with idiopathic parkinsonism, tremor, stiffness and slowed movement showed a positive course during thymalin treatment.

    Peptide
    Thymalin
    Outcome
    DecreaseParkinsonian triad of symptoms (tremor, rigidity, hypokinesia)
    Study

    n = 15

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A positive time-related course was noted of the patients' general physical/mental well-being, parkinsonian triad of symptoms (tremor, rigidity, hypokinesia) associated with objective parameters characterizing the state of cerebral integrative functions (by the method of determining the biological ag…
    1 context sentence
    Summary · context
    Overall, fifteen patients with stage IB-2A (stages 1.5 to 2.5 as per UPDRS scale) idiopathic parkinsonism who ranged from 45 to 72 years old were examined before and after the course of treatment with thymalin.
  3. 03HumanNon-randomized trialEfficacy outcome

    In idiopathic parkinsonism, the positive course during thymalin treatment was associated with objective parameters of cerebral integrative function (biological age of the central nervous system).

    In plain wordsIn patients with idiopathic parkinsonism, symptom improvement during thymalin treatment was linked to objective measures of brain function.

    Peptide
    Thymalin
    Outcome
    Direction not reportedCerebral integrative function parameters
    Study

    n = 15

    Outcome group
    Aging markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A positive time-related course was noted of the patients' general physical/mental well-being, parkinsonian triad of symptoms (tremor, rigidity, hypokinesia) associated with objective parameters characterizing the state of cerebral integrative functions (by the method of determining the biological ag…
    1 context sentence
    Summary · context
    Overall, fifteen patients with stage IB-2A (stages 1.5 to 2.5 as per UPDRS scale) idiopathic parkinsonism who ranged from 45 to 72 years old were examined before and after the course of treatment with thymalin.
  4. 04HumanNon-randomized trialActivity measurement

    In idiopathic parkinsonism, thymalin treatment significantly reduced anterocentral alpha rhythm power on EEG mapping.

    In plain wordsIn patients with idiopathic parkinsonism, thymalin treatment reduced alpha brain-wave power in the front and central brain regions.

    Peptide
    Thymalin
    Outcome
    DecreaseAnterocentral alpha rhythm power
    Study

    n = 15

    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Efficacy of thymolin use is confirmed by EEG mapping; there has been established a significant decrement in the power of alpha rhythm in the anterocentral regions of the brain, which fact suggests to us an improvement in the cortical neurodynamics.
    1 context sentence
    Summary · context
    Overall, fifteen patients with stage IB-2A (stages 1.5 to 2.5 as per UPDRS scale) idiopathic parkinsonism who ranged from 45 to 72 years old were examined before and after the course of treatment with thymalin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.